Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
Open Access
- 14 June 2019
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 8 (6) , e13464
Abstract
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Colon cancer treatment is dependent on stage at diagnosis. The current TNM (Tumour-Node-Metastasis) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision-making for chemotherapy will result in reducing over- and under-treatment. We developed a new, easy to apply, practice-changing method to select colon cancer patients for adjuvant (chemo)therapy: the tumour-stroma ratio (TSR). The TSR distinguishes within stage II-III patients who will likely benefit of adjuvant (chemo)therapy and from those who will not. Objective: The study goal is to add the TSR to current routine pathology evaluation in addition to the TNM classification. Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicentre study will validate the parameter prospectively. Methods: The study prepares for implementation of the TSR to current TNM guidelines, using routinely Haematoxylin and Eosin stained tumour tissue sections. Part 1. An E-learning module with a quality assessment program in the framework of the European Society of Pathology will be developed. This module will be used to assess the reliability and reproducibility of TSR, conducted by national and international pathologists. Part 2. Validation of the TSR in a prospective cohort of colon cancer pathological stage II-III patients in a multicentre setting. In total 1500 patients will be included. Results: The results of part 1 will be expected first half of 2019. For part 2, the inclusion was started end 2018 and will take 3 years, with an additional follow-up of 3 years. Conclusions: The main endpoints of this study are: Part 1. Instructed (international) pathologists who are able to reliably score TSR, resulting in low intra- and inter-observer variation. Part 2. Confirmation of significant survival differences for patients with a stroma-high tumour versus patients with a stroma-low tumour. Based on these findings modification in current treatment guidelines will be suggested. Clinical Trial: The Netherlands Trial Registry (NTR 7270). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=7270Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancerCurrent Opinion in Immunology, 2013
- The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trialAnnals of Oncology, 2012
- Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal CancerAnnals of Surgical Oncology, 2012
- The benefits and challenges associated with the use of drug delivery systems in cancer therapyBiochemical Pharmacology, 2010
- The proportion of tumour cells is an independent predictor for survival in colorectal cancer patientsBritish Journal of Cancer, 2010
- Tumor Budding as an Index to Identify High-Risk Patients with Stage II Colon CancerDiseases of the Colon & Rectum, 2008
- Drug Resistance and the Solid Tumor MicroenvironmentJNCI: Journal of the National Cancer Institute, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Hypoxia signalling in cancer and approaches to enforce tumour regressionNature, 2006